<?xml version="1.0" encoding="UTF-8"?>
<ref id="B21">
 <label>21.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Stroud</surname>
    <given-names>CR</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Hegde</surname>
    <given-names>A</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Cherry</surname>
    <given-names>C</given-names>
   </name>
  </person-group>
  <etal/>
  <article-title>Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade</article-title>. 
  <source>J. Oncol. Pharm. Pract.</source>
  <volume>25</volume>(
  <issue>3</issue>), 
  <fpage>551</fpage>â€“
  <lpage>557</lpage> (
  <year>2019</year>).
  <pub-id pub-id-type="pmid">29207939</pub-id>
 </mixed-citation>
</ref>
